JPWO2019173602A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019173602A5 JPWO2019173602A5 JP2020546962A JP2020546962A JPWO2019173602A5 JP WO2019173602 A5 JPWO2019173602 A5 JP WO2019173602A5 JP 2020546962 A JP2020546962 A JP 2020546962A JP 2020546962 A JP2020546962 A JP 2020546962A JP WO2019173602 A5 JPWO2019173602 A5 JP WO2019173602A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- virus
- alkyl
- different
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 69
- 241000700605 Viruses Species 0.000 claims 63
- -1 L-amino acid ester Chemical class 0.000 claims 58
- 125000000217 alkyl group Chemical group 0.000 claims 54
- 125000003118 aryl group Chemical group 0.000 claims 36
- 125000001072 heteroaryl group Chemical group 0.000 claims 33
- 125000000623 heterocyclic group Chemical group 0.000 claims 33
- 125000003342 alkenyl group Chemical group 0.000 claims 30
- 125000004452 carbocyclyl group Chemical group 0.000 claims 30
- 125000003545 alkoxy group Chemical group 0.000 claims 27
- 150000002632 lipids Chemical class 0.000 claims 27
- 150000003573 thiols Chemical class 0.000 claims 27
- 229910052736 halogen Inorganic materials 0.000 claims 26
- 150000002367 halogens Chemical class 0.000 claims 26
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 24
- 125000004093 cyano group Chemical group *C#N 0.000 claims 24
- 150000001925 cycloalkenes Chemical class 0.000 claims 24
- 125000000753 cycloalkyl group Chemical group 0.000 claims 24
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 24
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 24
- 125000000304 alkynyl group Chemical group 0.000 claims 21
- 125000005282 allenyl group Chemical group 0.000 claims 21
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 18
- 125000003282 alkyl amino group Chemical group 0.000 claims 18
- 125000004414 alkyl thio group Chemical group 0.000 claims 18
- 125000001769 aryl amino group Chemical group 0.000 claims 18
- 125000005110 aryl thio group Chemical group 0.000 claims 18
- 125000004104 aryloxy group Chemical group 0.000 claims 18
- 125000005366 cycloalkylthio group Chemical group 0.000 claims 18
- 125000005241 heteroarylamino group Chemical group 0.000 claims 18
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 18
- 125000005368 heteroarylthio group Chemical group 0.000 claims 18
- 125000004476 heterocycloamino group Chemical group 0.000 claims 18
- 125000004470 heterocyclooxy group Chemical group 0.000 claims 18
- 125000004468 heterocyclylthio group Chemical group 0.000 claims 18
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 18
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 16
- 206010014599 encephalitis Diseases 0.000 claims 16
- UGUUDTWORXNLAK-UHFFFAOYSA-N azidoalcohol Chemical compound ON=[N+]=[N-] UGUUDTWORXNLAK-UHFFFAOYSA-N 0.000 claims 15
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 15
- 150000002431 hydrogen Chemical class 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 229910052799 carbon Inorganic materials 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 14
- 125000002252 acyl group Chemical group 0.000 claims 12
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 12
- 150000002148 esters Chemical class 0.000 claims 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 12
- 150000002460 imidazoles Chemical class 0.000 claims 12
- 150000001345 alkine derivatives Chemical class 0.000 claims 9
- ICCBZGUDUOMNOF-UHFFFAOYSA-N azidoamine Chemical compound NN=[N+]=[N-] ICCBZGUDUOMNOF-UHFFFAOYSA-N 0.000 claims 9
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 150000007970 thio esters Chemical class 0.000 claims 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 8
- 230000009385 viral infection Effects 0.000 claims 7
- AFCCDDWKHLHPDF-UHFFFAOYSA-M metam-sodium Chemical class [Na+].CNC([S-])=S AFCCDDWKHLHPDF-UHFFFAOYSA-M 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- 241000709687 Coxsackievirus Species 0.000 claims 4
- 241000710827 Dengue virus 1 Species 0.000 claims 4
- 241000710815 Dengue virus 2 Species 0.000 claims 4
- 241000710872 Dengue virus 3 Species 0.000 claims 4
- 241000710844 Dengue virus 4 Species 0.000 claims 4
- 241000709661 Enterovirus Species 0.000 claims 4
- 241000991587 Enterovirus C Species 0.000 claims 4
- 241001335250 Heartland virus Species 0.000 claims 4
- 244000309467 Human Coronavirus Species 0.000 claims 4
- 241000712431 Influenza A virus Species 0.000 claims 4
- 241000713196 Influenza B virus Species 0.000 claims 4
- 241000710842 Japanese encephalitis virus Species 0.000 claims 4
- 206010023927 Lassa fever Diseases 0.000 claims 4
- 241000688852 Maporal virus Species 0.000 claims 4
- 201000009906 Meningitis Diseases 0.000 claims 4
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims 4
- 241000724205 Rice stripe tenuivirus Species 0.000 claims 4
- 241000315672 SARS coronavirus Species 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 4
- 241000710886 West Nile virus Species 0.000 claims 4
- 241000710772 Yellow fever virus Species 0.000 claims 4
- 201000003486 coccidioidomycosis Diseases 0.000 claims 4
- 230000000527 lymphocytic effect Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 229940051021 yellow-fever virus Drugs 0.000 claims 4
- BGPJLYIFDLICMR-UHFFFAOYSA-N 1,4,2,3-dioxadithiolan-5-one Chemical class O=C1OSSO1 BGPJLYIFDLICMR-UHFFFAOYSA-N 0.000 claims 3
- 241000712891 Arenavirus Species 0.000 claims 3
- 241000711573 Coronaviridae Species 0.000 claims 3
- 241000710831 Flavivirus Species 0.000 claims 3
- 241000713112 Orthobunyavirus Species 0.000 claims 3
- 241000709664 Picornaviridae Species 0.000 claims 3
- 241000711904 Pneumoviridae Species 0.000 claims 3
- 239000002202 Polyethylene glycol Chemical group 0.000 claims 3
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims 3
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims 3
- 150000007854 aminals Chemical class 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 3
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims 3
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims 3
- CWJSHJJYOPWUGX-UHFFFAOYSA-N chlorpropham Chemical compound CC(C)OC(=O)NC1=CC=CC(Cl)=C1 CWJSHJJYOPWUGX-UHFFFAOYSA-N 0.000 claims 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 3
- 229910052805 deuterium Inorganic materials 0.000 claims 3
- 150000002373 hemiacetals Chemical class 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000008177 pharmaceutical agent Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229920001223 polyethylene glycol Chemical group 0.000 claims 3
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 150000003555 thioacetals Chemical class 0.000 claims 3
- 150000003558 thiocarbamic acid derivatives Chemical class 0.000 claims 3
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 206010043554 thrombocytopenia Diseases 0.000 claims 2
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023176993A JP7786743B2 (ja) | 2018-03-07 | 2023-10-12 | ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 |
| JP2025207111A JP2026062641A (ja) | 2018-03-07 | 2025-11-27 | ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862639725P | 2018-03-07 | 2018-03-07 | |
| US62/639,725 | 2018-03-07 | ||
| PCT/US2019/021168 WO2019173602A1 (en) | 2018-03-07 | 2019-03-07 | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023176993A Division JP7786743B2 (ja) | 2018-03-07 | 2023-10-12 | ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021517132A JP2021517132A (ja) | 2021-07-15 |
| JPWO2019173602A5 true JPWO2019173602A5 (https=) | 2022-03-14 |
| JP2021517132A5 JP2021517132A5 (https=) | 2022-03-14 |
| JP7371931B2 JP7371931B2 (ja) | 2023-10-31 |
Family
ID=67846796
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546962A Active JP7371931B2 (ja) | 2018-03-07 | 2019-03-07 | ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 |
| JP2023176993A Active JP7786743B2 (ja) | 2018-03-07 | 2023-10-12 | ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 |
| JP2025207111A Pending JP2026062641A (ja) | 2018-03-07 | 2025-11-27 | ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023176993A Active JP7786743B2 (ja) | 2018-03-07 | 2023-10-12 | ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 |
| JP2025207111A Pending JP2026062641A (ja) | 2018-03-07 | 2025-11-27 | ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20210308168A1 (https=) |
| EP (1) | EP3762372A4 (https=) |
| JP (3) | JP7371931B2 (https=) |
| KR (2) | KR20260028884A (https=) |
| CN (2) | CN112074506B (https=) |
| AU (2) | AU2019231725B2 (https=) |
| BR (1) | BR112020018209A2 (https=) |
| CA (1) | CA3093222A1 (https=) |
| EA (1) | EA202092117A1 (https=) |
| GB (2) | GB2611644B (https=) |
| IL (1) | IL277160B2 (https=) |
| PH (1) | PH12020551404A1 (https=) |
| SG (1) | SG11202008527WA (https=) |
| WO (1) | WO2019173602A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3236972T3 (en) | 2014-12-26 | 2021-10-04 | Univ Emory | Antivirale N4-hydroxycytidin-derivativer |
| JP6804790B1 (ja) | 2017-12-07 | 2020-12-23 | エモリー ユニバーシティー | Ｎ４−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途 |
| US20210353660A1 (en) * | 2018-10-04 | 2021-11-18 | Octagon Therapeutics Inc. | Pre-Activated Nucleoside IMPDH Inhibitors As Anti-Infective Drugs |
| AU2020418425A1 (en) * | 2019-10-08 | 2022-04-14 | Emory University | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| CA3176661A1 (en) * | 2020-04-24 | 2021-10-28 | Memorial Sloan-Kettering Cancer Center | Targeted therapy for the treatment & prevention of life-threatening complications of infection |
| EP4203970A4 (en) * | 2020-08-27 | 2025-03-26 | Emory University | NEW FORMS OF ANTIVIRAL NUCLEOSIDES |
| CN114644666B (zh) * | 2020-12-18 | 2026-03-03 | 上海特化医药科技有限公司 | 5’-核苷前药的制备方法及中间体 |
| WO2022133205A1 (en) * | 2020-12-18 | 2022-06-23 | Merck Sharp & Dohme Corp. | Synthesis of antiviral nucleosides |
| CN112608357B (zh) * | 2020-12-21 | 2022-12-09 | 杭州科巢生物科技有限公司 | 一种抗病毒药物Molnupiravir的制备方法 |
| CN112778387A (zh) * | 2021-01-15 | 2021-05-11 | 杭州科巢生物科技有限公司 | 一种Molnupiravir晶型A及其制备方法 |
| WO2022174194A1 (en) * | 2021-02-15 | 2022-08-18 | Emory University | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| WO2022174179A1 (en) * | 2021-02-15 | 2022-08-18 | Emory University | 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| EP4319763A4 (en) * | 2021-04-09 | 2025-06-11 | Emory University | MODIFIED NUCLEOSIDES AND NUCLEOTIDE ANALOGUES AS ANTIVIRAL AGENT FOR CORONAVIRUS AND OTHER VIRUSES |
| US20240166680A1 (en) * | 2021-04-15 | 2024-05-23 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Nucleoside analog and use thereof |
| US11407779B1 (en) | 2021-04-23 | 2022-08-09 | Divi's Laboratories Ltd. | Process for the preparation of molnupiravir |
| CN112979733B (zh) * | 2021-04-25 | 2021-09-10 | 南京颐媛生物医学研究院有限公司 | 抗乙肝病毒的化合物及其制备方法和应用 |
| US20250281519A1 (en) * | 2021-05-05 | 2025-09-11 | Emory University | Nucleotide and nucleoside therapeutic compositions, combinations and uses related thereto |
| CN113278040B (zh) * | 2021-06-16 | 2022-07-05 | 苏州立新制药有限公司 | 5’-异丁酰基-n4-羟基胞苷的制备方法 |
| CN117642410A (zh) * | 2021-06-18 | 2024-03-01 | 苏州春海生物医药有限公司 | N4-羟基胞苷的酯衍生物及其用途 |
| WO2023012329A1 (en) | 2021-08-06 | 2023-02-09 | Intervet International B.V. | Method of treating veterinary viral diseases |
| CA3230382A1 (en) | 2021-09-08 | 2023-03-16 | Aligos Therapeutics, Inc. | Modified short interfering nucleic acid (sina) molecules and uses thereof |
| CN113880902A (zh) * | 2021-10-26 | 2022-01-04 | 江苏睿实生物科技有限公司 | 一种Molnupiravir药物中间体及其制备方法 |
| US11541071B1 (en) * | 2021-12-16 | 2023-01-03 | Ascletis BioScience Co., Ltd | Nucleoside derivatives and methods of use thereof |
| CN114478658A (zh) * | 2022-02-22 | 2022-05-13 | 苏州正济药业有限公司 | 一种莫那比拉韦的合成方法 |
| WO2023202604A1 (zh) * | 2022-04-20 | 2023-10-26 | 中国科学院上海药物研究所 | 抗病毒核苷类似物及其药物组合物和用途 |
| WO2024129985A2 (en) * | 2022-12-14 | 2024-06-20 | Lakewood Amedex, Inc. | Antiviral compounds, compositions, and uses thereof |
| KR20250127754A (ko) | 2022-12-23 | 2025-08-26 | 메이지 세이카 파루마 가부시키가이샤 | 에버멕틴 유도체 |
| WO2024182446A2 (en) | 2023-02-28 | 2024-09-06 | Aligos Therapeutics, Inc. | Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof |
| US20240352464A1 (en) | 2023-03-07 | 2024-10-24 | Aligos Therapeutics, Inc. | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof |
| MX2025013248A (es) * | 2023-05-05 | 2026-02-03 | Univ Emory | Composiciones terapéuticas de nucleótidos y nucleósidos que contienen 4'-halógeno y usos relacionados con estas |
| CN117567310A (zh) * | 2023-11-28 | 2024-02-20 | 重庆智合生物医药有限公司 | 一种神经酰胺np1的合成方法 |
| WO2025144872A2 (en) * | 2023-12-29 | 2025-07-03 | Adarx Pharmaceuticals, Inc. | Nucleoside-derived lipids for drug delivery |
| WO2026011167A1 (en) * | 2024-07-05 | 2026-01-08 | Emory University | Thionucleosides as antiviral agents |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4207363A1 (de) * | 1992-03-04 | 1993-09-09 | Max Delbrueck Centrum | Antivirale nucleosidanaloga, ihre herstellung und ihre pharmazeutische verwendung |
| EP1950563A3 (en) * | 2002-09-11 | 2008-08-06 | Michio Ishibashi | Method for screening for a substance for promoting regeneration of macrophages |
| EP2068912A2 (en) * | 2006-09-27 | 2009-06-17 | Coley Pharmaceutical Group, Inc. | Compositions of tlr ligands and antivirals |
| WO2009058800A2 (en) * | 2007-10-29 | 2009-05-07 | President And Fellows Of Harvard College | Synthesis of nucleosides |
| EP2342616A2 (en) * | 2008-09-23 | 2011-07-13 | Alnylam Pharmaceuticals Inc. | Chemical modifications of monomers and oligonucleotides with cycloaddition |
| MY171577A (en) | 2011-12-20 | 2019-10-21 | Hoffmann La Roche | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication |
| CA2873315A1 (en) | 2012-05-22 | 2013-11-28 | Idenix Pharamaceuticals, Inc. | D-amino acid compounds for liver disease |
| EP2935304A1 (en) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| GEP201706757B (en) * | 2012-12-21 | 2017-10-25 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| EP2981542B1 (en) * | 2013-04-01 | 2021-09-15 | Idenix Pharmaceuticals LLC | 2',4'-fluoro nucleosides for the treatment of hcv |
| EP2996695B1 (en) | 2013-05-16 | 2022-04-13 | Riboscience LLC | 4'-fluoro-2'-methyl substituted nucleoside derivatives |
| HK1224229A1 (zh) * | 2013-06-26 | 2017-08-18 | Alios Biopharma, Inc. | 取代的核苷，核苷酸及其类似物 |
| WO2015051169A2 (en) * | 2013-10-02 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
| EP3055319A4 (en) * | 2013-10-11 | 2018-01-10 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| LT3160476T (lt) * | 2014-06-24 | 2021-04-12 | Janssen Biopharma, Inc. | Pakeistieji nukleozidai, nukleotidai ir jų analogai, skirti naudoti virusinių infekcijų gydyme |
| TN2016000566A1 (en) | 2014-06-24 | 2018-04-04 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
| MA41441A (fr) | 2014-12-19 | 2017-12-12 | Alios Biopharma Inc | Nucléosides substitués, nucléotides et analogues de ceux-ci |
| WO2016134054A1 (en) * | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Anti-viral compounds |
| WO2016134056A1 (en) | 2015-02-18 | 2016-08-25 | Abbvie Inc. | Anti-viral compounds |
| EA201890454A1 (ru) * | 2015-08-06 | 2018-07-31 | Чимерикс, Инк. | Пирролопиримидиновые нуклеозиды и их аналоги, которые можно использовать в качестве противовирусных средств |
| WO2017040892A1 (en) * | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral compounds |
| WO2017040895A1 (en) | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral compounds |
| WO2017040896A1 (en) * | 2015-09-02 | 2017-03-09 | Abbvie Inc. | Anti-viral compounds |
| US11963972B2 (en) * | 2016-03-23 | 2024-04-23 | Emory University | Antiviral agents and nucleoside analogs for treatment of Zika virus |
| EP3471738A4 (en) * | 2016-06-20 | 2020-01-01 | Merck Sharp & Dohme Corp. | CYCLIC PHOSPHONATE-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR USE THEREOF FOR TREATING VIRUS DISEASES |
-
2019
- 2019-03-07 EP EP19764729.0A patent/EP3762372A4/en active Pending
- 2019-03-07 KR KR1020267004999A patent/KR20260028884A/ko active Pending
- 2019-03-07 WO PCT/US2019/021168 patent/WO2019173602A1/en not_active Ceased
- 2019-03-07 EA EA202092117A patent/EA202092117A1/ru unknown
- 2019-03-07 JP JP2020546962A patent/JP7371931B2/ja active Active
- 2019-03-07 GB GB2218405.5A patent/GB2611644B/en active Active
- 2019-03-07 CA CA3093222A patent/CA3093222A1/en active Pending
- 2019-03-07 CN CN201980030574.4A patent/CN112074506B/zh active Active
- 2019-03-07 US US16/979,108 patent/US20210308168A1/en not_active Abandoned
- 2019-03-07 IL IL277160A patent/IL277160B2/en unknown
- 2019-03-07 AU AU2019231725A patent/AU2019231725B2/en active Active
- 2019-03-07 GB GB2015827.5A patent/GB2589205B/en active Active
- 2019-03-07 CN CN202411351705.8A patent/CN119633010A/zh active Pending
- 2019-03-07 SG SG11202008527WA patent/SG11202008527WA/en unknown
- 2019-03-07 KR KR1020207028655A patent/KR20200140274A/ko not_active Ceased
- 2019-03-07 BR BR112020018209-5A patent/BR112020018209A2/pt active Search and Examination
-
2020
- 2020-09-07 PH PH12020551404A patent/PH12020551404A1/en unknown
-
2023
- 2023-07-26 US US18/359,435 patent/US20240180948A1/en active Pending
- 2023-10-12 JP JP2023176993A patent/JP7786743B2/ja active Active
-
2024
- 2024-09-19 AU AU2024219862A patent/AU2024219862A1/en active Pending
-
2025
- 2025-11-27 JP JP2025207111A patent/JP2026062641A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019173602A5 (https=) | ||
| JP2021517132A5 (https=) | ||
| JP5108750B2 (ja) | Ｈｄａｃ阻害剤の医薬製剤 | |
| US20110015273A1 (en) | Stable pharmaceutical aqueous compositions | |
| GB2589205A (en) | 4'-halogen containing nucleotide and nucleotide therapeutic compositions and uses related thereto | |
| JP2008522981A5 (https=) | ||
| JP2010528051A (ja) | デング感染症の治療または予防のための抗ウイルス薬 | |
| DE4218572A1 (de) | Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E | |
| BRPI0506705A (pt) | composto de tiouréias azabenzofuran-substituìdas, composições farmacêuticas e seus usos | |
| HRP20210942T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| CN102573794B (zh) | 供生理注射用的半胱氨酸 | |
| IL298673A (en) | Methods for treating the corona virus infection | |
| BR112012029212A2 (pt) | formulação de paracetamol injetável pronta para o uso estável | |
| EP1274421A2 (de) | Verwendung von substanzen, die als kaskaden-inhibitor der raf/mek/erk-signalkaskade wirken, zur herstellung eines arzneimittels gegen dna- und rna-viren. | |
| EA034559B1 (ru) | Жидкая фармацевтическая композиция, содержащая пеметрексед | |
| ES2584534A1 (es) | Formulación tópica oftálmica de bosentan | |
| ES2318277T3 (es) | Composicion farmaceutica que compresnde acido 5-metil-2-(2'-cloro-6'-fluoroanilino)fenilacetico. | |
| KR102605030B1 (ko) | 카바메이트 화합물을 포함하는 비경구용 액상 제제 | |
| TW200812592A (en) | Use of strobilurins for the treatment of disorders of iron metabolism | |
| CN106074506A (zh) | 盐酸阿比多尔在制备预防和治疗抗中东呼吸系统综合征冠状病毒的药物中的应用 | |
| US20060229356A1 (en) | Use of indomethacin and derivatives as broad-spectrum antiviral drugs and corresponding pharmaceutical compositions | |
| ES2388253A1 (es) | Ligandos sigma para la prevención o el tratamiento de dolor inducido por quimioterapia | |
| WO2019233474A1 (en) | Antiviral compounds and methods of use thereof | |
| JP6786504B2 (ja) | ウマにおける発熱の処置及び防止のための組成物及び方法 | |
| FI4081187T3 (fi) | Ibuprofeenia ja fenyyliefriiniä käsittävä nestemäinen koostumus |